CARDIOVASCULAR EVENT RISK REDUCTION WITH MEDICINES: DATA OF EVIDENCE BASED MEDICINE AND RECOMMENDATIONS TO PRACTITIONERS

CARDIOVASCULAR EVENT RISK REDUCTION WITH MEDICINES: DATA OF EVIDENCE BASED MEDICINE AND RECOMMENDATIONS TO PRACTITIONERS

Cardiovascular event risk reduction with medicines is discussed in the article. The role of randomized controlled trials is emphasized for estimation of therapy effects.

Bibliographic Details
Main Author:	S. Y. Martsevich
Format:	Article
Language:	English
Published:	Столичная издательская компания 2016-01-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	cardiovascular event risk medicines randomized controlled trials
Online Access:	https://www.rpcardio.online/jour/article/view/1142

Similar Items

ACHIEVEMENT OF LIPID TARGET PLASMA LEVELS IN PATIENTS OF HIGH CARDIOVASCULAR RISK: IS MEDICINE CHOICE IMPORTANT?
by: S. Y. Martsevich, et al.
Published: (2016-01-01)

Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
by: Volker Schirrmacher, et al.
Published: (2020-07-01)

Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines
by: Yu Tsung, et al.
Published: (2013-01-01)

A Cardiovascular Risk Score for Use in Occupational Medicine
by: Giuseppina Affinito, et al.
Published: (2021-06-01)

Chinese herbal medicine Shenqi compound for early intervention in patients at high cardiovascular risk of type 2 diabetes mellitus: the protocol of a multicenter, randomized, double-blind, placebo-controlled trial
by: Yulin Leng, et al.
Published: (2024-01-01)

Recommendations on the Clinical Trial Programme for Diabetes Medicines
by: I. A. Proskurina, et al.
Published: (2021-07-01)

Funding of Studies Supporting IA Guideline Recommendations in Cardiovascular Medicine—A Systematic Review
by: Emily P. Zeitler, et al.
Published: (2021-05-01)

Evolution of ideas on the assessment of cardiovascular risks in the perioperative period
by: V V Samoĭlenko, et al.
Published: (2014-04-01)

N-of-1 trials: The epitome of personalized medicine?
by: Joyce P. Samuel, et al.
Published: (2023-01-01)

History of evidence-based medicine
by: Roger L Sur, et al.
Published: (2011-01-01)

Does calcium intake affect cardiovascular risk factors and/or events?
by: Márcia Regina Simas Gonçalves Torres, et al.

The SMART Safety: An empirical dataset for evidence synthesis of adverse events
by: Shiqi Fan, et al.
Published: (2023-12-01)

Editorial: Efficacy and mechanism of herbal medicines and their functional compounds in preventing and treating cardiovascular diseases and cardiovascular disease risk factors
by: Tiantian Meng, et al.
Published: (2023-07-01)

Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis
by: Oh Chan Kwon, et al.
Published: (2020-07-01)

Utilization of cardiovascular medicines and cardiovascular mortality in Lithuania, Sweden and Norway in 2003–2012
by: Ingrida Lisauskienė, et al.
Published: (2017-07-01)

Cardiovascular Risk Prediction Models and Scores in the Era of Personalized Medicine
by: Areti Sofogianni, et al.
Published: (2022-07-01)

THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL INFARCTION. WHAT DO EVIDENCE-BASED MEDICINE DATA SPEAK FOR?
by: S. Yu. Martsevich
Published: (2016-01-01)

Ethical reflections on Evidence Based Medicine
by: S. Corrao
Published: (2013-05-01)

Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer – New Scientific Evidences or Another Example of “Pseudo-Evidence” Medicine?
by: S. Yu. Martsevich
Published: (2019-01-01)

Clinical studies of traditional Japanese herbal medicines (Kampo): Need for evidence by the modern scientific methodology
by: Ichiro Arai
Published: (2021-09-01)

THINKING ABOUT RANDOM EVENTS FROM A LOGICAL POINT OF VIEW
by: Rosario D'Amico
Published: (2013-06-01)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
by: Lingli Luo, et al.
Published: (2023-04-01)

DISCUSSION IDEAS ABOUT MEDICINE AMBIGUITIES
by: Yu. V. Muravyev, et al.
Published: (2017-10-01)

Editorial: Insights in General Cardiovascular Medicine: 2021
by: Lijun Wang, et al.
Published: (2022-07-01)

Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
by: Gurung, Resham L., et al.
Published: (2024)

Editorial: Precision Medicine in Chronic Inflammation
by: Oliver Distler, et al.
Published: (2021-09-01)

Simulation of a risk for cardiovascular diseases and their events at individual and group levels
by: S A Boĭtsov, et al.
Published: (2013-09-01)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
by: María Torrente, et al.
Published: (2022-12-01)

News of the Annual Congress of the European Society of Cardiology in Munich: Research to Help Practical Medicine
by: S. Yu. Martsevich
Published: (2018-11-01)

An Update on the Use of Artificial Intelligence in Cardiovascular Medicine
by: Shiavax J. Rao, et al.
Published: (2024-02-01)

Editorial: Highlights in General Cardiovascular Medicine: 2021
by: Lijun Wang, et al.
Published: (2022-05-01)

Integrating Evidence of the Traditional Chinese Medicine Collateral Disease Theory in Prevention and Treatment of Cardiovascular Continuum
by: Iokfai Cheang, et al.
Published: (2022-03-01)

High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
by: E. Reijnders, et al.
Published: (2023-10-01)

Adrian Grant’s pioneering use of evidence synthesis in perinatal medicine, 1980–1992
by: Iain Chalmers
Published: (2018-05-01)

Meta analysis of traditional Chinese medicine in the treatment of dry eye in recent years
by: Peng-Fei Jiang, et al.
Published: (2018-06-01)

Protocol of the SPARTE Study: A Strategy for Preventing Cardiovascular and Renal Events based on ARTErial Stiffness
by: Stephane Laurent, et al.
Published: (2020-07-01)

THE CHOICE OF DRUG FROM THE STANDPOINT OF EVIDENCE-BASED MEDICINE: CASE STUDY OF BETA-BLOCKERS
by: S. Yu. Martsevich, et al.
Published: (2016-01-01)

Predictive Value of the Cardio‐Ankle Vascular Index for Cardiovascular Events in Patients at Cardiovascular Risk
by: Toru Miyoshi, et al.
Published: (2021-08-01)

Access to Essential Medicines and Diagnostic Tests for Cardiovascular Diseases in Maputo City, Mozambique
by: Neusa Jessen, et al.
Published: (2023-02-01)

Lowered cognitive function and the risk of the first events of cardiovascular diseases: findings from a cohort study in Lithuania
by: Dalia Luksiene, et al.
Published: (2021-04-01)